Compare AbCellera Biologics Inc (ABCL) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Ulta Beauty Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Ulta Beauty Inc trades at $456.79 (market cap $19.51B). The key difference: Ulta Beauty Inc is far larger — about 8.3× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | ULTA | |
|---|---|---|
Market Cap | $2.35B | $19.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $706.82 |
52-Week Low | $2.78 | $450.75 |
Enterprise Value | $1.99B | $21.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ULTA Beauty trades at $453.78, down 1.64% recently, with a bearish technical signal from moving averages but oversold RSI near 29. The stock shows strong profitability with a 9.36% net margin and 47.45% ROE, though revenue growth slowed to $11.3B in 2025. Recent news highlights partnerships with Bath & Body Works and AI-driven loyalty initiatives to boost engagement.
Analysts remain bullish with a $623.73 consensus target, citing valuation discounts and market share gains. Risks include competitive pressures and margin compression, but the current P/E of 16.96 offers value if execution improves. The stock presents a contrarian opportunity amid negative sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
